X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (10087) 10087
Publication (1147) 1147
Book Review (232) 232
Newsletter (117) 117
Book Chapter (91) 91
Newspaper Article (31) 31
Book / eBook (27) 27
Conference Proceeding (22) 22
Transcript (14) 14
Dissertation (11) 11
Magazine Article (5) 5
Trade Publication Article (5) 5
Data Set (4) 4
Web Resource (3) 3
Reference (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7367) 7367
index medicus (7011) 7011
oncology (4339) 4339
cancer (3523) 3523
sorafenib (3137) 3137
animals (2459) 2459
female (2391) 2391
male (2363) 2363
antineoplastic agents - therapeutic use (2231) 2231
niacinamide - analogs & derivatives (2210) 2210
middle aged (1636) 1636
care and treatment (1589) 1589
protein kinase inhibitors - therapeutic use (1577) 1577
cell line, tumor (1448) 1448
aged (1446) 1446
research (1435) 1435
angiogenesis (1428) 1428
sunitinib (1415) 1415
antineoplastic agents - pharmacology (1414) 1414
pharmacology & pharmacy (1413) 1413
apoptosis (1306) 1306
metastasis (1278) 1278
tyrosine kinase inhibitor (1271) 1271
chemotherapy (1266) 1266
treatment outcome (1248) 1248
carcinoma, renal cell - drug therapy (1223) 1223
endothelial growth-factor (1195) 1195
kidney neoplasms - drug therapy (1184) 1184
mice (1175) 1175
tumors (1166) 1166
kinases (1147) 1147
adult (1114) 1114
vascular endothelial growth factor (1101) 1101
protein kinase inhibitors - pharmacology (1080) 1080
phenylurea compounds (1048) 1048
health aspects (1030) 1030
drug therapy (1019) 1019
bevacizumab (987) 987
angiogenesis inhibitors - therapeutic use (979) 979
antineoplastic agents (949) 949
therapy (942) 942
antineoplastic agents - adverse effects (939) 939
hepatocellular carcinoma (933) 933
neoplasms - drug therapy (890) 890
tyrosine kinase inhibitors (883) 883
liver neoplasms - drug therapy (879) 879
antimitotic agents (877) 877
signal transduction - drug effects (843) 843
expression (841) 841
carcinoma, hepatocellular - drug therapy (834) 834
cancer therapies (825) 825
cell proliferation - drug effects (807) 807
renal cell carcinoma (789) 789
analysis (786) 786
phase-ii trial (783) 783
targeted therapy (771) 771
renal-cell carcinoma (768) 768
mutation (766) 766
apoptosis - drug effects (765) 765
survival (765) 765
cell biology (762) 762
article (757) 757
molecular targeted therapy (756) 756
proteins (754) 754
protein kinase inhibitors - adverse effects (739) 739
inhibitor (732) 732
signal transduction (726) 726
tyrosine (726) 726
interferon-alpha (711) 711
inhibitors (708) 708
liver cancer (704) 704
review (694) 694
kidney neoplasms - pathology (692) 692
clinical trials (678) 678
antitumor-activity (656) 656
double-blind (656) 656
angiogenesis inhibitors (650) 650
pyridines - therapeutic use (646) 646
prognosis (634) 634
phase-ii (625) 625
liver neoplasms - pathology (624) 624
medicine (621) 621
carcinoma, renal cell (607) 607
phenylurea compounds - therapeutic use (607) 607
antineoplastic combined chemotherapy protocols - therapeutic use (604) 604
carcinoma, hepatocellular - pathology (600) 600
disease-free survival (598) 598
carcinoma (595) 595
aged, 80 and over (588) 588
clinical trials as topic (588) 588
development and progression (581) 581
research article (578) 578
biochemistry & molecular biology (569) 569
antineoplastic agents - administration & dosage (552) 552
indoles - therapeutic use (549) 549
benzenesulfonates - therapeutic use (538) 538
genetic aspects (538) 538
activation (534) 534
phosphorylation (523) 523
patients (521) 521
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (10083) 10083
French (102) 102
German (91) 91
Japanese (29) 29
Chinese (14) 14
Russian (14) 14
Korean (12) 12
Polish (10) 10
Spanish (9) 9
Hungarian (6) 6
Czech (5) 5
Italian (4) 4
Dutch (2) 2
Portuguese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Profiles of Drug Substances, Excipients and Related Methodology, ISSN 1871-5125, 2019, Volume 44, p. 239
Sorafenib (BAY-43-9006), marketed by Bayer as Nexavar® (USA), is anticancer drug approved by US-FDA for the treatment of unresectable hepatocellular carcinoma... 
Comprehensive profile | Clinical uses | Sorafenib | Hepatocellular carcinoma | Cancer drug | Drug-drug interactions | Pharmacology | Tyrosine kinase inhibitors | Sorafenib - chemistry | Antineoplastic Agents - pharmacology | Sorafenib - pharmacology | Antineoplastic Agents - chemistry
Journal Article
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 03/2006, Volume 7, Issue 4, pp. 453 - 461
Sorafenib is a small molecule inhibitor of several kinases involved in tumour proliferation and tumour angiogenesis including Raf, VEGFR and platelet derived... 
Raf kinase | renal cell carcinoma | sorafenib | VEGF | Renal cell carcinoma | Sorafenib | VON-HIPPEL-LINDAU | SUPPRESSOR GENE | DAYS ON/7 DAYS | ANTITUMOR-ACTIVITY | RENAL-CELL CARCINOMA | FACTOR RECEPTOR INHIBITOR | PHARMACOLOGY & PHARMACY | REFRACTORY SOLID TUMORS | PHASE-I | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | raf Kinases - antagonists & inhibitors | Humans | Pyridines - pharmacokinetics | Antineoplastic Agents - therapeutic use | Benzenesulfonates - therapeutic use | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | raf Kinases - metabolism | Benzenesulfonates - pharmacokinetics | Carcinoma, Hepatocellular - drug therapy | Receptors, Vascular Endothelial Growth Factor - metabolism | Receptors, Vascular Endothelial Growth Factor - antagonists & inhibitors | Carcinoma, Renal Cell - enzymology | Neovascularization, Pathologic - prevention & control | Antineoplastic Agents - pharmacokinetics | Carcinoma, Renal Cell - drug therapy | Carcinoma, Renal Cell - blood supply | Pyridines - therapeutic use | Protein Kinase Inhibitors - pharmacokinetics | Pyridines - administration & dosage | Drug Administration Schedule | Liver Neoplasms - drug therapy | Treatment Outcome | Randomized Controlled Trials as Topic | Xenograft Model Antitumor Assays | Protein Kinase Inhibitors - administration & dosage | Animals | Signal Transduction - drug effects | Protein Kinase Inhibitors - therapeutic use | Kidney Neoplasms - enzymology | Melanoma - drug therapy | Cell Line, Tumor | Cell Proliferation - drug effects | Kidney Neoplasms - drug therapy | Kidney Neoplasms - blood supply
Journal Article
DMW - Deutsche Medizinische Wochenschrift, ISSN 0012-0472, 09/2010, Volume 135, Issue 37, pp. 1819 - 1822
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2008, Volume 359, Issue 4, pp. 378 - 390
Journal Article
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9807, pp. 1931 - 1939
Journal Article
Blood, ISSN 0006-4971, 06/2012, Volume 119, Issue 22, pp. 5133 - 5143
Internal tandem duplication (ITD) of the fms-related tyrosine kinase-3 (FLT3) gene occurs in 30% of acute myeloid leukemias (AMLs) and confers a poor... 
FLT3 TYROSINE KINASE | INTERNAL TANDEM DUPLICATION | ADULT PATIENTS | ACTIVATING MUTATION | INHIBITOR PKC412 | ALDEHYDE DEHYDROGENASE-ACTIVITY | ACUTE MYELOGENOUS LEUKEMIA | TISSUE INHIBITOR | RISK MYELODYSPLASTIC SYNDROME | PROGNOSTIC-SIGNIFICANCE | HEMATOLOGY | Niacinamide - analogs & derivatives | fms-Like Tyrosine Kinase 3 - antagonists & inhibitors | Neoplasm Transplantation | Humans | Middle Aged | Aldehyde Dehydrogenase - biosynthesis | Matrix Metalloproteinase 15 - genetics | Male | Transplantation, Heterologous | Bone Marrow - enzymology | Gene Expression Profiling | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Benzenesulfonates - administration & dosage | Benzenesulfonates - adverse effects | Janus Kinase 3 - biosynthesis | fms-Like Tyrosine Kinase 3 - genetics | Leukemia, Myeloid, Acute - enzymology | Pyridines - adverse effects | Time Factors | Antineoplastic Agents - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Protein Structure, Tertiary | Pyridines - administration & dosage | Leukemia, Myeloid, Acute - pathology | Aldehyde Dehydrogenase - genetics | Gene Expression Regulation, Leukemic | Mice, SCID | fms-Like Tyrosine Kinase 3 - metabolism | Matrix Metalloproteinase 15 - biosynthesis | Drug Resistance, Neoplasm - genetics | Animals | Bone Marrow - pathology | Janus Kinase 3 - genetics | Mice, Inbred NOD | Mice | Mutation | Drug Resistance, Neoplasm - drug effects | Leukemia, Myeloid, Acute - genetics
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 01/2007, Volume 356, Issue 2, pp. 125 - 134
Journal Article